ten Hoorn, Sanne http://orcid.org/0000-0001-9553-6091
Sommeijer, Dirkje W.
Elliott, Faye
Fisher, David
de Back, Tim R.
Trinh, Anne
Koens, Lianne
Maughan, Tim
Seligmann, Jenny http://orcid.org/0000-0003-4379-6005
Seymour, Matthew T.
Quirke, Phil
Adams, Richard
Richman, Susan D.
Punt, Cornelis J. A.
Vermeulen, Louis http://orcid.org/0000-0002-6066-789X
Funding for this research was provided by:
KWF Kankerbestrijding (KWF 10529)
ZonMw (Vidi 016.156.308)
Innovatiefonds Zorgverzekeraars (B17-140)
The European Research Council
Article History
Received: 30 March 2021
Revised: 8 June 2021
Accepted: 30 June 2021
First Online: 12 July 2021
Ethics approval and consent to participate
: Both the COIN and the PICCOLO trial obtained written informed consent from all patients to participate in the studies. Both trials were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: LV received speaker and consultancy fees from Genentech, Bayer, Servier, Boehringer-Ingelheim, MSD and Pierre Fabre. LV received unrestricted grants from Novartis, Servier, Roche and Roche Diagnostics. LV declares ongoing collaborations with Firalis, LeadPharma and Genentech. RA received speaker and consultancy fees form Amgen, Bayer, Astra Zeneca, Merck. TM received unrestricted grants and speaker fees from Merck KGaA, and unrestricted grants and consultancy fees from AstraZeneca. CP reports an advisory role for Nordic Pharma. PQ has research funding with Roche, GeneFirst and Amgen, previous research funding from Halio, consultancy with Nordlai‐Adlyte and advisory boards with Merck, Amgen and Roche. JS received speaker fees from Merck Serono; advisory board—Pierre Fabre, Roche; CME—GI Connect. No disclosures were reported by the other authors. None of the funders had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.